Percy Ivy

7.9k total citations
120 papers, 4.5k citations indexed

About

Percy Ivy is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Percy Ivy has authored 120 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 48 papers in Molecular Biology and 30 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Percy Ivy's work include Cancer Treatment and Pharmacology (26 papers), Colorectal Cancer Treatments and Studies (21 papers) and Cancer therapeutics and mechanisms (17 papers). Percy Ivy is often cited by papers focused on Cancer Treatment and Pharmacology (26 papers), Colorectal Cancer Treatments and Studies (21 papers) and Cancer therapeutics and mechanisms (17 papers). Percy Ivy collaborates with scholars based in United States, Canada and New Zealand. Percy Ivy's co-authors include Tracy T. Batchelor, Rakesh K. Jain, A. Gregory Sorensen, Edward A. Sausville, Joseph E. Tomaszewski, Patrick Y. Wen, Marek Ancukiewicz, Dan G. Duda, Elizabeth R. Gerstner and Jay S. Loeffler and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Percy Ivy

116 papers receiving 4.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Percy Ivy United States	36	1.9k	1.5k	883	869	731	120	4.5k
Anthony M. Magliocco Canada	38	1.3k 0.7×	1.8k 1.2×	1.1k 1.2×	853 1.0×	388 0.5×	136	4.2k
Steffen Hauptmann Germany	42	2.1k 1.1×	1.4k 0.9×	634 0.7×	1.0k 1.2×	153 0.2×	111	4.9k
Jennifer J. Wheler United States	42	3.2k 1.7×	2.6k 1.8×	1.8k 2.0×	2.1k 2.4×	446 0.6×	199	6.7k
S. Percy Ivy United States	43	4.1k 2.2×	3.6k 2.4×	1.3k 1.5×	1.3k 1.5×	399 0.5×	189	7.9k
L. Campion France	42	2.2k 1.2×	1.9k 1.3×	1.2k 1.4×	1.4k 1.6×	355 0.5×	185	6.2k
William P. Tong United States	40	3.6k 1.9×	2.1k 1.4×	1.4k 1.6×	641 0.7×	276 0.4×	110	6.6k
Tomas Radivoyevitch United States	30	1.3k 0.7×	791 0.5×	542 0.6×	549 0.6×	904 1.2×	156	3.4k
Anil Potti United States	31	2.7k 1.4×	2.1k 1.4×	1.2k 1.3×	1.4k 1.7×	318 0.4×	103	5.3k
Paula M. Fracasso United States	31	1.0k 0.5×	1.6k 1.1×	477 0.5×	380 0.4×	136 0.2×	109	3.0k
Barbara A. Conley United States	39	2.3k 1.2×	2.7k 1.8×	1.5k 1.6×	1.3k 1.5×	319 0.4×	143	6.0k

Countries citing papers authored by Percy Ivy

Since Specialization

Citations

This map shows the geographic impact of Percy Ivy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Percy Ivy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Percy Ivy more than expected).

Fields of papers citing papers by Percy Ivy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Percy Ivy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Percy Ivy. The network helps show where Percy Ivy may publish in the future.

Co-authorship network of co-authors of Percy Ivy

This figure shows the co-authorship network connecting the top 25 collaborators of Percy Ivy. A scholar is included among the top collaborators of Percy Ivy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Percy Ivy. Percy Ivy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shah, Nirali N., Percy Ivy, Rebecca A. Enos, et al.. (2020). Expanded access trial of tocilizumab in COVID19+hospitalized cancer patients. Clinical Cancer Research. 26(18). 1 indexed citations

Kiesel, Brian F., Robert A. Parise, Liza C. Villaruz, et al.. (2017). LC–MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 146. 244–250. 5 indexed citations

LoConte, Noelle K., Albiruni R. Abdul Razak, Percy Ivy, et al.. (2014). A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Investigational New Drugs. 33(1). 169–176. 33 indexed citations

Castonguay, Vincent, Stéphanie Lheureux, Stephen Welch, et al.. (2014). A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: A study of the Princess Margaret, Chicago and California Consortia. Gynecologic Oncology. 134(2). 274–280. 43 indexed citations

Lam, Catherine G., Wayne L. Furman, Chong Wang, et al.. (2014). Phase I Clinical Trial of Ifosfamide, Oxaliplatin, and Etoposide (IOE) in Pediatric Patients With Refractory Solid Tumors. Journal of Pediatric Hematology/Oncology. 37(1). e13–e18. 5 indexed citations

Lu‐Emerson, Christine, Matija Snuderl, Nathaniel D. Kirkpatrick, et al.. (2013). Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro-Oncology. 15(8). 1079–1087. 177 indexed citations

Emblem, Kyrre E., Kim Mouridsen, Atle Bjørnerud, et al.. (2013). Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nature Medicine. 19(9). 1178–1183. 176 indexed citations

Stein, Stacey, Amy Tiersten, Howard S. Höchster, et al.. (2013). A Phase 2 Study of Oxaliplatin Combined With Continuous Infusion Topotecan for Patients With Previously Treated Ovarian Cancer. International Journal of Gynecological Cancer. 23(9). 1577–1582. 10 indexed citations

Sorensen, A. Gregory, Kyrre E. Emblem, Pavlina Polaskova, et al.. (2011). Increased Survival of Glioblastoma Patients Who Respond to Antiangiogenic Therapy with Elevated Blood Perfusion. Cancer Research. 72(2). 402–407. 241 indexed citations

10.

Batchelor, Tracy T., Dan G. Duda, Emmanuelle di Tomaso, et al.. (2010). Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma. Journal of Clinical Oncology. 28(17). 2817–2823. 406 indexed citations

11.

Nock, Charles, Joanna M. Brell, Joseph A. Bokar, et al.. (2009). A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors. Investigational New Drugs. 29(1). 126–130. 17 indexed citations

12.

McGregor, Lisa M., Sheri L. Spunt, Wayne L. Furman, et al.. (2009). Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors. Cancer. 115(8). 1765–1775. 14 indexed citations

13.

Blank, Stephanie V., Paul J. Christos, Mimi Kim, et al.. (2009). Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: A New York Cancer Consortium Study. Gynecologic Oncology. 116(3). 442–446. 16 indexed citations

14.

Mackay, Helen, Anna V. Tinker, Eric Winquist, et al.. (2009). A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecologic Oncology. 116(2). 163–167. 86 indexed citations

15.

Matulonis, Ursula A., Suzanne Berlin, Carolyn Krasner, et al.. (2007). Phase II study of Cediranib (RECENTIN™, AZD2171) in recurrent epithelial ovarian cancer. Molecular Cancer Therapeutics. 6. 1 indexed citations

16.

Vidal, Laura, Hal W. Hirte, Gini F. Fleming, et al.. (2007). A Phase 2 study of AZD2171 in recurrent or persistent ovarian, peritoneal or fallopian tube cancer. A study of the PMH, Chicago, and California Phase II Consortia. Molecular Cancer Therapeutics. 6. 1 indexed citations

17.

Goel, Sanjay, Scott Wadler, Anthony Hoffman, et al.. (2003). A Phase II Study of Rebeccamycin Analog NSC 655649 in Patients with Metastatic Colorectal Cancer. Investigational New Drugs. 21(1). 103–107. 19 indexed citations

18.

Mani, Sridhar, Martin A. Graham, David B. Bregman, Percy Ivy, & Stephen G. Chaney. (2002). Oxaliplatin: A Review of Evolving Concepts. Cancer Investigation. 20(2). 246–263. 55 indexed citations

19.

Shalaby‐Rana, Eglal, Dena M. Selby, Percy Ivy, et al.. (1996). Multilocular thymic cyst in a child with acquired immunodeficiency syndrome. The Pediatric Infectious Disease Journal. 15(1). 83–86. 9 indexed citations

20.

Ebb, David H., Harry Kerasidis, Gilbert Vézina, et al.. (1992). Spinal cord compression in widely metastatic Wilms' tumor. Paraplegia in two children with anaplastic wilms' tumor. Cancer. 69(11). 2726–2730. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact